Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease
Sponsor: YangPan
Summary
The aim of this study is to explore the effects of the dual orexin receptor antagonist Lemborexant on improving motor and sleep comorbidity in patients with Parkinson's disease. This study will provide clinical evidence for the application of dual orexin receptor antagonists in the treatment of Parkinson's Disease.
Official title: Study for the Dual Orexin Receptor Antagonist Lemborexant in Improving Motor-Sleep Comorbidity in Parkinson's Disease
Key Details
Gender
All
Age Range
50 Years - Any
Study Type
INTERVENTIONAL
Enrollment
44
Start Date
2026-03-19
Completion Date
2026-12-01
Last Updated
2026-03-23
Healthy Volunteers
No
Interventions
Lemborexant
Participants will receive oral Lemborexant (5 mg/day) nightly approximately 5-30 minutes before going to bed for 28 consecutive days.
placebo
Participants will receive a matching placebo nightly approximately 5-30 minutes before going to bed for 28 consecutive days.
Locations (1)
Zhongnan hospital
Wuhan, Hubei, China